Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Janssen (J&J Innovative Medicine)

Status

Conditions: Respiratory Syncytial Virus

Treatments: Drug: JNJ-53718678

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04221412

CR108653

53718678RSV4001 (Other Identifier)

Details and patient eligibility

About

The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus [RSV] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria